Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Studying Allegra For Dermatitis And Asthma, Firm Tells OTC Cmte.

Executive Summary

Aventis is pursuing an atopic dermatitis indication for the antihistamine Allegra, Senior VP-Medical & Regulatory Francois Nader, MD, told the FDA OTC switch advisory committee May 11.
Advertisement

Related Content

Pfizer Zyrtec-D Labeled "Rx-only" Pending Antihistamine OTC Switch Decision
Pfizer Zyrtec-D Labeled "Rx-only" Pending Antihistamine OTC Switch Decision
House Rx Hearing Topics Include Generics, DTC And Antihistamine OTC Switch
House Rx Hearing Topics Include Generics, DTC And Antihistamine OTC Switch
Drug Labeling Must Be Controlled By Sponsors, Not FDA, Petition Says
Drug Labeling Must Be Controlled By Sponsors, Not FDA, Petition Says
Antihistamine OTC Switch Moves To Legal Arena After Committee Votes
Antihistamine OTC Switch Moves To Legal Arena After Committee Votes
Advertisement
UsernamePublicRestriction

Register

PS037849

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel